MedPath

InhaleRx's IRX-211 Receives Approval for Phase II Breakthrough Cancer Pain Trial; Neurotech's NTI164 Shows Promise in PANDAS/PANS

• InhaleRx's IRX-211 drug-device combination has been approved for a Phase II clinical trial to treat breakthrough cancer pain (BTcP) in patients, addressing a critical need for non-opioid options. • The trial will assess the safety, efficacy, and optimal dosing of IRX-211, aiming to provide rapid and reliable pain relief without the severe side effects associated with opioid-based treatments. • Neurotech International's NTI164 cannabinoid drug candidate demonstrated modulation of the immune system and epigenetic factors in children with PANDAS/PANS in a Phase I/II trial. • Genomic analysis of NTI164 reinforces its safety and efficacy by showing no activation of damaging cellular pathways, with plans to submit the findings to a leading scientific journal.

InhaleRx has received approval from the Human Research Ethics Committee (HREC) to commence a Phase II clinical trial for its IRX-211 drug-device medication, targeting patients suffering from breakthrough cancer pain (BTcP). This trial aims to evaluate the safety, efficacy, and dosing of IRX-211 in managing BTcP, an acute and intense pain that significantly impacts the lives of cancer patients and is often challenging to manage with conventional pain therapies.

InhaleRx's IRX-211 Trial Details

BTcP affects a substantial portion of cancer patients globally, with an estimated total addressable market exceeding US$1 billion, according to InhaleRx. The trial represents a significant step toward providing a non-opioid alternative for pain management. Darryl Davies, CEO of InhaleRx, stated that "IRX-211 has the potential to redefine how breakthrough cancer pain is managed, addressing a critical gap in the market currently for safe, fast-acting, non-opioid treatments." He further emphasized the company's commitment to delivering a therapeutic solution that offers reliable relief without the dependency risks and severe side effects linked to opioid-based treatments like fentanyl.

Neurotech International's NTI164 in PANDAS/PANS

Neurotech International has announced the results of genomic analysis from a Phase I/II clinical trial of its NTI164 cannabinoid drug candidate in patients with Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS). The study revealed that NTI164 modulates the immune system, protein translation, and epigenetic factors at both the gene expression (genomic) and protein (proteomic) levels in children with PANDAS/PANS.
The data indicates that NTI164 is safe and effective under the inflammatory conditions characteristic of PANDAS/PANS, with no activation of potentially damaging cellular pathways. Neurotech anticipates compiling and submitting the genomic analysis results to a leading scientific journal in the near future.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Intensity Therapeutics' Sarcoma Trial INT230-6 Authorized to Continue by DMC

Intensity Therapeutics' Phase 3 INVINCIBLE-3 study of INT230-6 in soft tissue sarcoma is authorized to continue without modifications after a Data Monitoring Committee review.
The global, randomized trial compares intratumoral INT230-6 to standard-of-care chemotherapy in patients with leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma.

Interius BioTherapeutics' INT2104 In Vivo CAR-T Therapy Trial Expands to Europe

Interius BioTherapeutics received approval from the Paul Ehrlich Institute in Germany to expand its Phase 1 INVISE trial of INT2104 to Europe.
INT2104 is a first-in-class in vivo CAR gene therapy targeting CD20-positive B cells for treating B-cell malignancies.

First-In-Human Trial of TherVacB Hepatitis B Vaccine Shows Promise

TherVacB, a novel therapeutic vaccine, has entered its first in-human clinical trial, offering potential for a hepatitis B cure.
The vaccine aims to activate CD4 T-cells, addressing the global impact of chronic hepatitis B, which affects over 300 million people.

Neurology News: ShiraTronics' Migraine Device Trial, QurAlis' ALS Therapy, and Anavex's Alzheimer's Drug Application

ShiraTronics has initiated its RELIEV-CM2 study, implanting its neuromodulation device in chronic migraine patients across the US and Australia to assess therapeutic effects.
QurAlis' QRL-201, designed to restore STATHMIN-2 expression, advances to the dose range-finding phase of its ANQUR trial for ALS after successful dose-escalation.

Alnylam's ALN-HTT02: First Patient Dosed in Phase 1 Huntington's Disease Trial

Alnylam Pharmaceuticals initiated a Phase 1 clinical trial for ALN-HTT02, a novel RNAi therapeutic targeting the huntingtin (HTT) gene for Huntington's disease (HD).
The trial aims to assess the safety and tolerability of ALN-HTT02 in up to 54 participants with Stage 2 or early Stage 3 HD, aged 25-70, across sites in the UK and Canada.

Neurotech Receives Approval to Commence Human Pharmacokinetic Study of NTI164

Neurotech has received ethics approval to begin a human pharmacokinetic study of its drug NTI164 in Adelaide.
NTI164, an oral cannabinoid drug, is being developed for neurological disorders involving neuroinflammation.

InhaleRx Secures Funding for Phase 2 Trials of IRX-211 in Breakthrough Cancer Pain

InhaleRx secured $38.5 million from Clendon Biotech Capital to advance clinical trials for IRX-211, targeting breakthrough cancer pain, and IRX-616a, addressing unmet medical needs.
Phase 2 clinical trials for IRX-211, a drug-device combination, are set to commence, evaluating its efficacy and safety in opioid-tolerant patients with breakthrough cancer pain.

InhaleRx Secures $38.5M Funding to Advance Inhaled Therapies for Cancer Pain and Panic Disorder

InhaleRx has secured $38.5 million in funding from Clendon Biotech Capital to advance its inhaled therapies, IRX-211 and IRX-616a, through Phase 2 clinical trials.
IRX-211 is being developed for breakthrough cancer pain in opioid-tolerant patients, offering rapid relief through precise medication delivery.

Roche's Subcutaneous Tecentriq Approved; Gilead's HIV Shot Shows Promise

The FDA approved Roche's Tecentriq Hybreza, the first checkpoint inhibitor available as a subcutaneous injection, offering a faster administration time of about seven minutes.
Gilead's twice-yearly lenacapavir HIV shot reduced infection risk by 96% in a Phase 3 trial, leading to halted trial and plans for regulatory filings and a potential 2025 launch.

Tonix Pharmaceuticals' Tonmya™ Receives Conditional FDA Acceptance for Fibromyalgia Treatment

Tonix Pharmaceuticals' TNX-102 SL, conditionally named Tonmya™, has received FDA acceptance as a trade name for fibromyalgia management.
Two positive Phase 3 trials demonstrated Tonmya's potential as a novel, first-line treatment option for fibromyalgia, affecting millions in the U.S.

Reference News

[1]
News in brief: InhaleRx; Neurotech International - Cannabiz
cannabiz.com.au · Nov 18, 2024

InhaleRx's IRX-211 drug-device medication for breakthrough cancer pain receives HREC approval for Phase II trial. Neurot...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy